Enorama Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Enorama Pharma has a total shareholder equity of SEK19.5M and total debt of SEK436.0K, which brings its debt-to-equity ratio to 2.2%. Its total assets and total liabilities are SEK34.4M and SEK14.8M respectively.
Key information
2.2%
Debt to equity ratio
kr436.00k
Debt
Interest coverage ratio | n/a |
Cash | kr6.15m |
Equity | kr19.54m |
Total liabilities | kr14.85m |
Total assets | kr34.39m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ERMA's short term assets (SEK13.0M) exceed its short term liabilities (SEK10.2M).
Long Term Liabilities: ERMA's short term assets (SEK13.0M) exceed its long term liabilities (SEK4.6M).
Debt to Equity History and Analysis
Debt Level: ERMA has more cash than its total debt.
Reducing Debt: ERMA's debt to equity ratio has reduced from 9.1% to 2.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ERMA has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ERMA is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.